Search results for

The much awaited Anti-Monopoly Law of China was promulgated on August 31 2007. It will come into effect on August 1 2008.

October 1 2007 heralded the coming into force of amendments to sections 39, 41(1) and 42(1) of the Trade-marks Regulations. Simultaneously, a new Opposition Board Practice Notice came into effect.

A majority of the Full Federal Court recently extended the boundaries of contributory infringement in Australia.

A monthly column devoted to IP curiosities and controversies, named in honour of John of Utynam - who received the world's first recorded patent in 1449

Angola (AO) became the 138th PCT contracting state on September 27 2007. The PCT will enter into force for Angola on December 27 2007 and the country may be designated in PCT international applications from this date. However, the law in Angola has not yet been amended to recognize the PCT and if national phase applications are filed, it is uncertain whether or not any enforceable rights will be granted. While Angola is not a member of the Paris Union, the Angolan authorities have indicated the priority of an earlier foreign application may be claimed within 12 months of the filing of that earlier application. Until the law has been amended to provide for PCT national phase applications, it is recommended that national patent applications be filed within the 12-month priority period.

Australian universities and research institutes have a great deal to offer businesses - as long as their lawyers negotiate the right kind of deal. Peter Hallett and John Golding of Watermark provide a guide

Australia's courts have handed down three key trade mark-related rulings in the past year. Lance Scott of Spruson & Ferguson explains what lessons they have for IP owners

The Australian Patents Act 1990 has a number of generous provisions that can provide patentees with enormous benefits if used properly. Unfortunately, many clients are unaware of the rules. Stuart Boyer of Griffith Hack explains how to make the most of the law

null

Opponents of biotech research have focused on ethical provisions in European law to challenge controversial patents. Eklavya Gupte reports on two pending cases at the EPO that may clarify some key questions